WO2023053007 - DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES
National phase entry:
Publication Number
WO/2023/053007
Publication Date
06.04.2023
International Application No.
PCT/IB2022/059202
International Filing Date
27.09.2022
Title **
[English]
DIOXAZINES AND THEIR USE IN TREATMENT OF GBA-RELATED DISEASES
[French]
DIOXAZINES ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES ASSOCIÉES À GBA
Applicants **
ZEVRA DENMARK A/S
Inventors
NEVE, Søren
BROWN, William Dalby
THIRSTRUP, Kenneth
Priority Data
21199449.6
28.09.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3000 | |
| EPO | Filing, Examination, Granting | 12401 | |
| Japan | Filing, Examination, Granting | 2134 | |
| South Korea | Filing, Examination, Granting | 1914 | |
| USA | Filing, Examination, Granting | 5640 |
Total:
25,089
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to dioxazines, their synthesis, and their use for increasing GBA activity and/or levels as well as treatment of GBA-related diseases, such as Parkinson's disease.[French]
La présente invention concerne des dioxazines, leur synthèse et leur utilisation pour augmenter l'activité et/ou les niveaux de GBA, ainsi que le traitement de maladies associées à GBA, telles que la maladie de Parkinson.